<DOC>
	<DOCNO>NCT02523092</DOCNO>
	<brief_summary>The objective study test whether use Acthar gel context sarcoidosis lead improve symptom lung function correlate decrease level predictive blood biomarkers , like chemokine ligand 9 ( CXCL9 ) .</brief_summary>
	<brief_title>Use CXCL9 Biomarker Acthar Efficacy</brief_title>
	<detailed_description>The investigator test whether Acthar gel 's anti-inflammatory property modulate immune cell lead decrease blood biomarkers improvement clinical parameter . Specific Aim 1 examine level predictive biomarker , chemokine ligand 9 ( CXCL9 ) , related transcript , determine whether decrease participant time take Acthar . Specific Aim 2 test whether biologic change measure blood correlate clinical marker , include lung function symptom score . Since investigator find CXCL9 predict clinical course , hypothesize CXCL9 transcript level blood decrease time pulmonary sarcoidosis participant whose clinical outcome measure improve Acthar .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Biopsyproven diagnosis sarcoidosis demonstrate pulmonary involvement Refractoriness intolerance immunosuppressive agent like prednisone methotrexate Smoking Cancer Chronic infection ( e.g . tuberculosis , viral , fungal , bacterial ) Inflammatory condition Coexisting lung disease Congestive heart failure Uncontrolled hypertension Recent surgery Active peptic ulcer Osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>sarcoidosis</keyword>
	<keyword>Acthar</keyword>
	<keyword>CXCL9</keyword>
	<keyword>chemokine ligand 9</keyword>
</DOC>